<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004992</url>
  </required_header>
  <id_info>
    <org_study_id>(IND) - DPP (completed)</org_study_id>
    <secondary_id>U01DK048489</secondary_id>
    <nct_id>NCT00004992</nct_id>
  </id_info>
  <brief_title>Diabetes Prevention Program</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Minority Health and Health Disparities (NIMHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Research on Women's Health (ORWH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Diabetes Prevention Program is a nationwide clinical study to answer the question: Can
      Type 2 diabetes (also called noninsulin-dependent or adult-onset diabetes) be prevented or
      delayed? The study has recruited volunteers, who are at high risk of developing diabetes, at
      twenty-five medical centers in the United States. It is sponsored by the National Institute
      of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, and other
      Institute and corporate sponsors. Researchers will evaluate the efficacy of a lifestyle
      intervention and a pharmacological intervention in preventing or delaying Type 2 diabetes in
      persons with impaired glucose tolerance (IGT). Each person in the study will be followed for
      3 to 6 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 1996</start_date>
  <completion_date type="Actual">April 2001</completion_date>
  <primary_completion_date type="Actual">April 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of diabetes</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Diabetes was diagnosed on the basis of an annual oral glucose-tolerance test or a semiannual fasting plasma glucose test, according to the 1997 criteria of the American Diabetes Association</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3234</enrollment>
  <condition>Diabetes Mellitus, Non-Insulin-Dependent</condition>
  <condition>Glucose Intolerance</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive Lifestyle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intensive lifestyle</intervention_name>
    <arm_group_label>Intensive Lifestyle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Impaired glucose tolerance (fasting plasma glucose 95-125 mg/dL and 2hr plasma glucose
             140-199 mg/dL)

          -  BMI &gt;= 24 kg/m2

        Exclusion Criteria:

          -  Underlying disease likely to limit life span and/or increase risk of interventions

          -  Conditions or behaviors likely to effect conduct of the DPP

          -  Diabetes or disordered glucose metabolism

          -  Suboptimally treated Thyroid disease

          -  Fasting triglyceride level &lt; 600 mg/dl

          -  Exclusions related to medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Fowler, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington University Biostatistics Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>George Washington University Biostatistics Center, Suite 750, 6110 Executive Blvd</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR, Knowler WC, Nathan DM, Altshuler D; Diabetes Prevention Program Research Group. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med. 2006 Jul 20;355(3):241-50.</citation>
    <PMID>16855264</PMID>
  </results_reference>
  <results_reference>
    <citation>Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.</citation>
    <PMID>11832527</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2000</study_first_submitted>
  <study_first_submitted_qc>March 17, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2000</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>clinical trial</keyword>
  <keyword>multi-center</keyword>
  <keyword>NIDDM</keyword>
  <keyword>NIDDK</keyword>
  <keyword>Diabetes Prevention Program (DPP)</keyword>
  <keyword>diabetes risk factors</keyword>
  <keyword>diabetes</keyword>
  <keyword>glycemia</keyword>
  <keyword>cardiovascular risk factors</keyword>
  <keyword>quality of life</keyword>
  <keyword>physical activity and nutrition</keyword>
  <keyword>occurrence of adverse events</keyword>
  <keyword>insulin secretion and sensitivity</keyword>
  <keyword>prevention</keyword>
  <keyword>abnormal glucose metabolism</keyword>
  <keyword>lifestyle intervention</keyword>
  <keyword>drug intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

